A new survey by GEN reveals 35 active drug development programs in North America, Europe and China. Those 35 include treatments that have received the greatest public attention in recent days, being developed by companies that range from pharma giants like GlaxoSmithKline and Sanofi, to small and large biotechs such as Moderna, Inc. and Gilead Sciences.